Burning Rock Biotech Ltd
Burning Rock Biotech Ltd is a precision oncology company focused on applying next-generation sequencing to cancer care. Its business centers on therapy selection testing for late-stage cancer patients and on cancer early detection, with operations organized around clinical and research channels in China.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNGS-based diagnostic tests that help identify treatment options for late-stage cancer patients.
Testing delivered through hospital channels for oncology diagnosis and treatment support.
Reference laboratory testing performed through centralized facilities for oncology samples.
Testing and analytical services provided to biopharma clients for clinical research programs.
Products
Reported · share of revenue- Services58.6 %
- Products41.4 %
Source: 20-F FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Burning Rock sells to hospitals, oncology physicians, and other healthcare providers that need sequencing-based cancer testing to guide treatment decisions. It also serves pharmaceutical and biotechnology customers that use its testing capabilities in clinical research and drug development. Its early-detection products are aimed at clinical use in cancer screening and validation settings.
Buy sequencing-based oncology tests for diagnosis and therapy selection inside hospital workflows.
Use centralized testing services for patient samples and outsourced oncology diagnostics.
Purchase testing support for R&D, clinical trials, and biomarker-related research.
Engage for clinical validation and deployment of early detection assays.
Strategy
Burning Rock’s strategy is to deepen its role in precision oncology by combining therapy-selection testing with early detection capabilities. It also appears focused on expanding distribution through hospital and central laboratory channels while advancing early detection from R&D toward clinical validation. The business depends on translating sequencing technology into routine clinical use and broader adoption by physicians and health systems.
Routine use by oncologists and hospitals is essential for durable demand.
Clinical validation is the step between research and scalable diagnostic revenue.
Multiple delivery channels improve access to customers and test utilization.
Geography
2024The company’s operating footprint is centered in China, where its oncology testing products are delivered through hospital and central-laboratory channels. It is incorporated in the United States and listed on Nasdaq, but its business activity and clinical customer base are concentrated in Greater China. That geographic concentration ties performance to Chinese healthcare adoption, regulation, and reimbursement dynamics.
Share of the revenue the company reports by geography.
Risks
Burning Rock faces the usual risks of a diagnostics company tied to clinical adoption, regulation, reimbursement, and the pace at which physicians incorporate new tests into care pathways. Its concentration in China adds exposure to healthcare policy changes, while early detection remains dependent on successful validation and eventual commercialization. As an oncology sequencing business, it also depends on continued technology relevance and the accuracy and utility of its assays.
- Slow adoption of oncology sequencing testsImpact: HighLikelihood: Medium
Revenue depends on hospitals and physicians incorporating NGS into routine care.
Exposure: Therapy selection testing and in-hospital channels
- China healthcare policy and reimbursement changesImpact: HighLikelihood: Medium
The customer base is concentrated in China, where policy affects test access and pricing.
Exposure: Core operating market
- Early detection commercialization failureImpact: HighLikelihood: Medium
The early-detection program is still in clinical validation and may not scale successfully.
Exposure: Cancer early detection
- Technology and competitive obsolescenceImpact: MediumLikelihood: Medium
Sequencing-based diagnostics require continuous technical relevance and clinical utility.
Exposure: NGS testing platform
Accounting
Judgemental itemsCentral lab, hospital, and pharma R&D services may have different timing and contract terms.
Impact: Can shift reported revenue between periods
Management excludes depreciation and amortization from gross profit presentation.
Impact: Affects comparability with GAAP gross margin
Sequencing assets and early-detection programs may require ongoing assessment of recoverability.
Impact: Could affect expense recognition and carrying values
Similar listed companies
Publicly listed companies with a comparable business focus.
iTonic Holdings Ltd
ITOC · Electromedical & Electrotherapeutic Apparatus
iTonic Holdings Ltd is a U.S.-listed healthcare solutions company organized around Beijing Feitian Zhaoye Technology Co., Ltd., its wholly owned operating subsidiary in Beijing, China.
NeoGenomics, Inc
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
CG Oncology, Inc.
CGON · Biological Products, (No Diagnostic Substances)
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
Last updated: 28/09/2026